Table 1. Cell viability of bone marrow... | American Society of Hematology

Table 1.

Cell viability of bone marrow samples from primary AML blasts

	% Blasts	Control IDN-1529			Ara-C IDN-1529			Dox IDN-1529			Vincristine IDN-1529
Bone marrow	% Blasts		−	+	−	+	−	+	−	+	−	+
Patient 1	91					—	—	—	—
Cell count		100	82.5	35.9 ^*	32.0 ^*					69.9 ^*	66.0 ^*
Annexin V+		13.5	7.3	63.5 ^*	50.0 ^*					24.2 ^*	13.3 ^*
CMXRos-MTG
R1		73.5	77.7	16.9 ^*	24.3 ^*					59.0 ^*	67.7 ^*
R2		3.7	4.8	4.3 ^*	11.5 ^*					5.5 ^*	7.0 ^*
R3		21.1	15.0	77.1 ^*	59.8 ^*					33.4 ^*	23.3 ^*
Patient 2	82					—	—	—	—
Cell count		100	92.4	82.3	96.8					83.1	85.8
Annexin V+		13.4	7.1	14.6	14.7					10.3	10.3
CMXRos-MTG
R1		19.1	22.5	27.5	18.7					19.7	24.7
R2		56.6	59.1	37.4	48.7					61.4	56.4
R3		21.7	15.4	30.6	28.4					15.8	17.5
Patient 3	78					—	—	—	—
Cell count		100	103.4	106.7	101.1					112.4	101.1
Annexin V+		4.7	2.3	7.7	5.5					6.3	3.4
CMXRos-MTG
R1		86.8	82.9	85.9	86.3					89.0	84.2
R2		6.7	13.2	8.2	8.4					6.5	11.9
R3		2.6	2.3	4.0	3.4					3.3	2.4
Patient 4	41							—	—
Cell count		100	101.0	88.5	89.6	46.9 ^*	57.3 ^*			96.9	99.0
Annexin V+		15.4	14.6	15.8	16.4	36.6 ^*	28.2 ^*			14.5	11.3
CMXRos-MTG
R1		95.8	95.3	93.3	94.0	89.0 ^*	76.0 ^*			96.0	94.8
R2		3.7	4.3	6.02	5.0	10.2 ^*	23.4 ^*			3.5	4.6
R3		0.01	0.03	0.07	0.08	0.01 ^*	0.01 ^*			0.11	0.11
Patient 5	82
Cell count		100	110.0	40.0 ^*	39.0 ^*	49.0 ^*	47.0 ^*	70.0 ^*	65.0 ^*	69.0 ^*	68.0 ^*
Annexin V+		15.2	4.3	78.9 ^*	30.6 ^*	58.7 ^*	30.5 ^*	19.0 ^*	13.2 ^*	17.6 ^*	13.1 ^*
CMXRos-MTG
R1		93.6	93.6	8.7 ^*	48.8 ^*	41.3 ^*	53.7 ^*	78.2 ^*	73.0 ^*	78.8 ^*	70.6 ^*
R2		1.4	2.0	13.2 ^*	9.3 ^*	6.9 ^*	9.1 ^*	7.0 ^*	5.3 ^*	5.1 ^*	5.4 ^*
R3		3.1	2.1	75.7 ^*	38.6 ^*	41.3 ^*	32.1 ^*	11.5 ^*	18.8 ^*	12.5 ^*	20.4 ^*

	% Blasts	Control IDN-1529			Ara-C IDN-1529			Dox IDN-1529			Vincristine IDN-1529
Bone marrow	% Blasts		−	+	−	+	−	+	−	+	−	+
Patient 1	91					—	—	—	—
Cell count		100	82.5	35.9 ^*	32.0 ^*					69.9 ^*	66.0 ^*
Annexin V+		13.5	7.3	63.5 ^*	50.0 ^*					24.2 ^*	13.3 ^*
CMXRos-MTG
R1		73.5	77.7	16.9 ^*	24.3 ^*					59.0 ^*	67.7 ^*
R2		3.7	4.8	4.3 ^*	11.5 ^*					5.5 ^*	7.0 ^*
R3		21.1	15.0	77.1 ^*	59.8 ^*					33.4 ^*	23.3 ^*
Patient 2	82					—	—	—	—
Cell count		100	92.4	82.3	96.8					83.1	85.8
Annexin V+		13.4	7.1	14.6	14.7					10.3	10.3
CMXRos-MTG
R1		19.1	22.5	27.5	18.7					19.7	24.7
R2		56.6	59.1	37.4	48.7					61.4	56.4
R3		21.7	15.4	30.6	28.4					15.8	17.5
Patient 3	78					—	—	—	—
Cell count		100	103.4	106.7	101.1					112.4	101.1
Annexin V+		4.7	2.3	7.7	5.5					6.3	3.4
CMXRos-MTG
R1		86.8	82.9	85.9	86.3					89.0	84.2
R2		6.7	13.2	8.2	8.4					6.5	11.9
R3		2.6	2.3	4.0	3.4					3.3	2.4
Patient 4	41							—	—
Cell count		100	101.0	88.5	89.6	46.9 ^*	57.3 ^*			96.9	99.0
Annexin V+		15.4	14.6	15.8	16.4	36.6 ^*	28.2 ^*			14.5	11.3
CMXRos-MTG
R1		95.8	95.3	93.3	94.0	89.0 ^*	76.0 ^*			96.0	94.8
R2		3.7	4.3	6.02	5.0	10.2 ^*	23.4 ^*			3.5	4.6
R3		0.01	0.03	0.07	0.08	0.01 ^*	0.01 ^*			0.11	0.11
Patient 5	82
Cell count		100	110.0	40.0 ^*	39.0 ^*	49.0 ^*	47.0 ^*	70.0 ^*	65.0 ^*	69.0 ^*	68.0 ^*
Annexin V+		15.2	4.3	78.9 ^*	30.6 ^*	58.7 ^*	30.5 ^*	19.0 ^*	13.2 ^*	17.6 ^*	13.1 ^*
CMXRos-MTG
R1		93.6	93.6	8.7 ^*	48.8 ^*	41.3 ^*	53.7 ^*	78.2 ^*	73.0 ^*	78.8 ^*	70.6 ^*
R2		1.4	2.0	13.2 ^*	9.3 ^*	6.9 ^*	9.1 ^*	7.0 ^*	5.3 ^*	5.1 ^*	5.4 ^*
R3		3.1	2.1	75.7 ^*	38.6 ^*	41.3 ^*	32.1 ^*	11.5 ^*	18.8 ^*	12.5 ^*	20.4 ^*

AML blasts were treated with Ara-C (2 μM), Dox (500 ng/mL), vincristine (10 ng/mL), or paclitaxel (50 ng/mL) with or without caspase inhibitor IDN-1529 (20 μM) at 48 hours. Results are expressed as percentages. — indicates not done.

Samples responded to the drugs.

View Large

This Feature Is Available To Subscribers Only